1795 – Positron emission tomography / computed tomography (PET/CT) dopaminergic imaging for evaluating Parkinsonism

New Medicare Benefits Schedule item.

Position emission tomography dopaminergic imaging is a way of diagnosing Parkinson disease from non-Parkinson disease, so that the correct treatments can be used and started earlier, potentially making a difference to the quality of life of those affected.

Type: Investigative

Parkinson disease, in some cases, is not easy to diagnose because the signs and symptoms are not always standard and there are other conditions that can mimic the disease. Evaluating Parkinsonism may help some patients with a diagnosis of Parkinson disease who do not respond to standard treatment.

The following consultation deadlines apply:

• Pre-PASC consultation deadline: 14 March 2025
• Pre-MSAC consultation deadline: -

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 16 to 17 April 2025
• ESC meeting: -
• MSAC meeting: -

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.